The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on their ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Keytruda is not chemotherapy. It’s a type of treatment called immunotherapy. It works with the body’s immune system, helping T cells fight cancer cells. With immunotherapy, the body’s immune system ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-approved indications, the drug is showing it still has unfinished business. In the ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...